BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2025 3:37:30 AM | Browse: 14 | Download: 52
 |
Received |
|
2024-12-31 04:08 |
|
Peer-Review Started |
|
2024-12-31 04:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-02-19 07:31 |
|
Revised |
|
2025-02-25 03:17 |
|
Second Decision |
|
2025-03-25 02:37 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-03-25 07:33 |
|
Articles in Press |
|
2025-03-25 07:33 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-04-28 02:43 |
|
Publish the Manuscript Online |
|
2025-05-20 03:37 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Xiao Ni, Jia-Ju Xu, Yu Pang and Jia-Ju Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Fund of Tai’an Science and Technology Agency |
2019NS180 |
|
| Corresponding Author |
Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an Central Hospital Affiliated to Qingdao University, No. 29 Longtan Road, Taishan District, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com |
| Key Words |
Triple negative breast cancer; Phosphoinositide 3-kinase; Protein kinase B; Mechanistic target of rapamycin; Biomarkers; Natural products; Inhibitors; Therapy |
| Core Tip |
Triple-negative breast cancer is an aggressive subtype of breast cancer with a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway regulates cell proliferation, growth, metabolism, and survival. This review analyzes biomarkers associated with this pathway in triple-negative breast cancer, including proteins, mRNA, non-coding RNA, and transcription factors. Furthermore, it systematically examines key natural products targeting the pathway, such as flavonoids, terpenoids, and alkaloids. Finally, it provides a comprehensive overview of inhibitors used to target the PI3K/AKT/mTOR pathway, including PI3K, mTOR, dual PI3K/mTOR, and AKT inhibitors. |
| Publish Date |
2025-05-20 03:37 |
| Citation |
<p>Ni CX, Xu JJ, Pang Y, Xu JJ. Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer. <i>World J Clin Oncol</i> 2025; 16(5): 104623</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i5/104623.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i5.104623 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
